Amundi Purchases 127,236 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Amundi has increased its stake in Bristol Myers Squibb by 2.5%, owning 5,266,884 shares valued at approximately $304.53 million.
• Recent insider trading reveals that EVP David V. Elkins sold 56,000 shares for about $2.65 million, reducing his ownership by over 25%.
• Analysts have adjusted their ratings on Bristol Myers Squibb, with several downgrades and a consensus price target of $56.38 despite a solid earnings report last quarter.

Amundi raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 2.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 5,266,884 shares of the biopharmaceutical company's stock after acquiring an additional 127,236 shares during the period. Amundi owned about 0.26% of Bristol Myers Squibb worth $304,534,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. Brighton Jones LLC raised its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after acquiring an additional 4,935 shares during the period. Bank Pictet & Cie Europe AG bought a new position in Bristol Myers Squibb during the 4th quarter worth $13,094,000. Cary Street Partners Financial LLC bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth $2,301,000. BOKF NA raised its stake in Bristol Myers Squibb by 1.4% in the fourth quarter. BOKF NA now owns 103,029 shares of the biopharmaceutical company's stock valued at $5,752,000 after purchasing an additional 1,464 shares in the last quarter. Finally, Centiva Capital LP grew its stake in Bristol Myers Squibb by 8.7% during the fourth quarter. Centiva Capital LP now owns 19,671 shares of the biopharmaceutical company's stock worth $1,113,000 after buying an additional 1,580 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.07% of the company's stock.

Bristol Myers Squibb Trading Down 1.0%

Shares of BMY stock traded down $0.46 during trading on Monday, hitting $46.68. 9,877,265 shares of the stock traded hands, compared to its average volume of 13,052,685. The firm's fifty day moving average price is $47.09 and its 200-day moving average price is $50.44. The firm has a market capitalization of $95.02 billion, a P/E ratio of 18.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a $0.62 dividend. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Analyst Ratings Changes

Several brokerages have recently issued reports on BMY. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup reduced their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Daiwa Capital Markets cut Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of "Hold" and an average target price of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.